Results 71 to 80 of about 411,617 (199)

Improved Cardiovascular and Cardiometabolic Risk in Patients With Type 1 Diabetes and Autoimmune Polyglandular Syndrome Switched From Glargine to Degludec Due to Hypoglycaemic Variability

Frontiers in Endocrinology, 2018
Background: Cardiovascular disease is a frequent complication of type 1 diabetes (T1D). We evaluated the effectiveness of switching from glargine to degludec in reducing the cardiovascular risk factors, the Framingham risk score (FRS) and visceral ...
Valentina Guarnotta, Giulia Di Bella, Giuseppe Pillitteri, Alessandro Ciresi, Carla Giordano   +4 more
doaj   +1 more source

Improved health status with insulin degludec compared with insulin glargine in people with Type 1 diabetes

, 2012
Aims: The efficacy and safety of insulin degludec (degludec), a new-generation ultra-long-acting basal insulin, was compared with insulin glargine (glargine) in people with Type 1 diabetes mellitus in a 16-week, open-label, randomized trial.
K. I. Birkeland, P. D. Home, Meneghini, L.,, L. Meneghini, Birkeland, K. I.,, U. Wendisch, J. Jendle, Home, P. D.,, T. Johansen, Johansen, T.,, T. E. Christensen, A. P. Roberts, Wendisch, U.,, Roberts, A. P.,, Ratner, R. E.,, Christensen, T. E.,, Jendle, Johan,, R. E. Ratner   +17 more
core   +1 more source

Kajian literatur efektivitas dan keamanan insulin degludec pada pasien diabetes melitus [PDF]

, 2021
Diabetes melitus adalah kelompok penyakit metabolisme yang dikarakterisasi oleh hiperglikemia akibat dari efek sekresi insulin, atau karena kerja dari insulin maupun keduanya.
Atwinda, Estisan Septyana
core  

[Basal insulin degludec (Tresiba®)].

, 2019
Insulin degludec (Tresiba®) is characterized by an original mode of prolonged and continuous insulin release after its subcutaneous injection. Thereby, it has a very long glucose-lowering effect, around 42 hours, and a better reproducibility from both a ...
Scheen, A.J., Mathieu, C.
core  

Risk factors for kidney disorders in patients with type 2 diabetes at high cardiovascular risk: An exploratory analysis (DEVOTE 12)

Diabetes & Vascular Disease Research, 2020
Aim: To investigate risk factors associated with kidney disorders in patients with type 2 diabetes (T2D) at high cardiovascular (CV) risk. Methods: In DEVOTE, a cardiovascular outcomes trial, 7637 patients were randomised to insulin degludec (degludec ...
Aslam Amod, John B Buse, Darren K McGuire, Thomas R Pieber, Rodica Pop-Busui, Richard E Pratley, Bernard Zinman, Marco Bo Hansen, Ting Jia, Thomas Mark, Neil R Poulter,   +11 more
doaj   +1 more source

Basal insulin degludec (Tresiba(R))

, 2019
peer reviewedInsulin degludec (Tresiba(R)) is characterized by an original mode of prolonged and continuous insulin release after its subcutaneous injection.
Scheen, André, Mathieu, Chantal
core  

Ligand-Controlled Assembly of Hexamers, Dihexamers, and Linear Multihexamer Structures by the Engineered Acylated Insulin Degludec

, 2012
Insulin degludec, an engineered acylated insulin, was recently reported to form a soluble depot after subcutaneous injection with a subsequent slow release of insulin and an ultralong glucose-lowering effect in excess of 40 h in humans.
Friderichsen, A. V., Schluckebier, G., Gerd Schluckebier, Ib Jonassen, Jens K. Thomsen, Havelund, S., Mathias Norrman, Steensgaard, D. B., Jonassen, I., Thomsen, J. K., Anders V. Friderichsen, Svend Havelund, Strauss, H. M., Norrman, M., Dorte B. Steensgaard, Holger M. Strauss   +15 more
core   +1 more source

Use of insulin degludec, a new basal insulin with an ultra-long duration of action, in basal-bolus therapy in type 1 and type 2 diabetes.

, 2013
International audienceInsulin degludec is a new basal insulin analogue with an ultra-long duration of action that provides a flat and stable action profile with a duration of action greater than 42hours. Two clinical trials comparing insulin degludec and
Marre, Michel, Kerlan, Véronique, Gouet, Didier, Renard, Eric   +3 more
core   +1 more source

Insulin degludec/insulin aspart is the first co-formulation of basal and prandial insulin analogues

Сахарный диабет, 2014
Achievement of glycemic control is the major therapeutic aim to prevent or delay the onset and progression of diabetes related complications. Insulin therapy represents a cornerstone in the treatment of diabetes and has been used widely for achieving ...
Ivan Ivanovich Dedov, Marina Vladimirovna Shestakova   +1 more
doaj   +1 more source

Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes:a randomised trial

, 2012
Insulin degludec/insulin aspart (IDegAsp) is a soluble co-formulation of insulin degludec (70%) and insulin aspart (IAsp: 30%). Here, we compare the efficacy and safety of IDegAsp, an alternative IDegAsp formulation (AF: containing 45% IAsp), and ...
Leiter, Lawrence A, Muñoz-Torres, Manuel, Niskanen, Leo, Franek, Edward, Endahl, Lars, Skjoth, Trine Vang, Skjøth, Trine Vang, Vaag, Allan, Weng, Jianping, Damci, Taner, Leiter, Lawrence A., Donnet, Jean-Paul   +11 more
core   +1 more source